178 related articles for article (PubMed ID: 20088797)
1. Gammadelta T cell modulation in anticancer treatment.
Caccamo N; Dieli F; Meraviglia S; Guggino G; Salerno A
Curr Cancer Drug Targets; 2010 Feb; 10(1):27-36. PubMed ID: 20088797
[TBL] [Abstract][Full Text] [Related]
2. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors.
Bonneville M; Scotet E
Curr Opin Immunol; 2006 Oct; 18(5):539-46. PubMed ID: 16870417
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
Braza MS; Klein B
Br J Haematol; 2013 Jan; 160(2):123-32. PubMed ID: 23061882
[TBL] [Abstract][Full Text] [Related]
4. [Tgammadelta lymphocytes in oncology: unconventional killer lymphocytes].
Catros V; Toutirais O; Bouet F; Cabillic F; Desille M; Fournié JJ
Med Sci (Paris); 2010 Feb; 26(2):185-91. PubMed ID: 20188051
[TBL] [Abstract][Full Text] [Related]
5. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application.
Gomes AQ; Martins DS; Silva-Santos B
Cancer Res; 2010 Dec; 70(24):10024-7. PubMed ID: 21159627
[TBL] [Abstract][Full Text] [Related]
6. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
[TBL] [Abstract][Full Text] [Related]
7. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo.
Kabelitz D; Wesch D; Pitters E; Zöller M
J Immunol; 2004 Dec; 173(11):6767-76. PubMed ID: 15557170
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
[TBL] [Abstract][Full Text] [Related]
9. gammadelta T cells in cancer immunotherapy: current status and future prospects.
Chiplunkar S; Dhar S; Wesch D; Kabelitz D
Immunotherapy; 2009 Jul; 1(4):663-78. PubMed ID: 20635991
[TBL] [Abstract][Full Text] [Related]
10. γδ T Cells in Tumor Microenvironment.
Imbert C; Olive D
Adv Exp Med Biol; 2020; 1273():91-104. PubMed ID: 33119877
[TBL] [Abstract][Full Text] [Related]
11. Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer.
Hoeres T; Smetak M; Pretscher D; Wilhelm M
Front Immunol; 2018; 9():800. PubMed ID: 29725332
[TBL] [Abstract][Full Text] [Related]
12. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.
Rischer M; Pscherer S; Duwe S; Vormoor J; Jürgens H; Rossig C
Br J Haematol; 2004 Aug; 126(4):583-92. PubMed ID: 15287953
[TBL] [Abstract][Full Text] [Related]
13. Innate T cell immunity to HIV-infection. Immunotherapy with phosphocarbohydrates, a novel strategy of immune intervention?
Gougeon ML; Malkovsky M; Casetti R; Agrati C; Poccia F
Vaccine; 2002 May; 20(15):1938-41. PubMed ID: 11983250
[TBL] [Abstract][Full Text] [Related]
14. Opportunities and challenges in development of phosphoantigens as Vγ9Vδ2 T cell agonists.
Wiemer DF; Wiemer AJ
Biochem Pharmacol; 2014 Jun; 89(3):301-12. PubMed ID: 24680696
[TBL] [Abstract][Full Text] [Related]
15. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.
Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E
J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120
[TBL] [Abstract][Full Text] [Related]
16. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
Viey E; Fromont G; Escudier B; Morel Y; Da Rocha S; Chouaib S; Caignard A
J Immunol; 2005 Feb; 174(3):1338-47. PubMed ID: 15661891
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity.
Galluzzo S; Santini D; Vincenzi B; Caccamo N; Meraviglia F; Salerno A; Dieli F; Tonini G
Expert Opin Ther Targets; 2007 Jul; 11(7):941-54. PubMed ID: 17614762
[TBL] [Abstract][Full Text] [Related]
18. γδ T cells in cancer immunotherapy.
Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
[TBL] [Abstract][Full Text] [Related]
19. Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: doubts no more.
Caccamo N; Meraviglia S; Scarpa F; La Mendola C; Santini D; Bonanno CT; Misiano G; Dieli F; Salerno A
Expert Opin Biol Ther; 2008 Jul; 8(7):875-83. PubMed ID: 18549319
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells.
Poccia F; Gioia C; Martini F; Sacchi A; Piacentini P; Tempestilli M; Agrati C; Amendola A; Abdeddaim A; Vlassi C; Malkovsky M; D'Offizi G
AIDS; 2009 Mar; 23(5):555-65. PubMed ID: 19238075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
